Group 1 - The innovative pharmaceutical ETF (560900) has seen a 2.20% increase as of May 29, 2025, with significant trading volume [1] - The CSI Innovative Pharmaceutical Industry Index (931152) rose by 2.32%, with notable gains from constituent stocks such as Zhixiang Jintai (688443) up 8.91%, Sangfor Technologies (688336) up 7.41%, and Maiwei Biotech (688062) up 5.78% [1] - Over the past two weeks, the innovative pharmaceutical ETF (560900) has accumulated a 3.94% increase, ranking it among the top comparable funds [2] Group 2 - CITIC Securities believes that leading innovative pharmaceutical companies have entered a profit phase, with potential for nonlinear profit explosions as commercialization expands [2] - The investment opportunities in the innovative pharmaceutical sector are linked to the clinical progress of molecules under research and the entire commercialization phase, which can last up to ten years [2] - The innovative pharmaceutical ETF closely tracks the CSI Innovative Pharmaceutical Industry Index, which selects no more than 50 representative listed companies involved in innovative drug research and development [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality technology companies amid a new wave of AI-driven technological advancements [2] - Various actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund and the Morgan Smart Connectivity Fund, which targets opportunities in artificial intelligence [3] - The Morgan Hang Seng Technology ETF (513890) and the Morgan CSI Innovative Pharmaceutical Industry ETF (560900) provide passive investment options for technology and innovative pharmaceutical sectors, respectively [3]

Group 1 - The core viewpoint is that the pharmaceutical industry is expected to experience stable growth driven by innovation, policy optimization, and increasing clinical demand due to aging demographics [3] - The National Biopharmaceutical Index (399441) has shown a strong increase of 1.83%, with key stocks like Kylin Pharmaceutical (002821) rising by 5.51% and Zhaoyan New Drug (603127) by 4.66% [1] - The Biopharmaceutical ETF (159839) has seen a cumulative increase of 1.54% over the past two weeks, indicating positive market sentiment [1] Group 2 - Open Source Securities emphasizes that the pharmaceutical sector will benefit from improved drug procurement policies and a favorable external environment, leading to a recovery in the healthcare industry [3] - Citic Securities notes that the pharmaceutical sector achieved its best market returns in the first half of 2025, driven by policy trends and the maturation of pharmaceutical innovation [3] - The current PEG levels for most growth-oriented pharmaceutical companies are below 1, suggesting potential for performance and valuation recovery [3]

Summary of Key Points Core Viewpoint The announcement details the changes in the registered capital and governance structure of Dize Pharmaceutical Co., Ltd., including the cancellation of the supervisory board and amendments to the company's articles of association. Group 1: Changes in Registered Capital - The company completed a private placement of restricted shares on April 18, 2025, increasing the total number of shares by 41.7648 million [1]. - The registered capital increased from RMB 417,648,086 to RMB 459,412,894 [1][2]. Group 2: Cancellation of Supervisory Board - The company will no longer have a supervisory board, with its functions being transferred to the audit committee of the board of directors [1][2]. - This change is in accordance with the Company Law and the revised guidelines for listed companies [1]. Group 3: Amendments to Articles of Association - The company revised its articles of association and related rules, including the shareholder meeting rules and board meeting rules, while abolishing the supervisory board meeting rules [2][3]. - The amendments aim to enhance the governance structure and align with current legal requirements [2][3].

Core Viewpoint - The document outlines the insider information management system of Dize (Jiangsu) Pharmaceutical Co., Ltd., emphasizing the importance of confidentiality and compliance with relevant laws and regulations to protect investors' rights and ensure fair information disclosure. Group 1: Insider Information Management - The board of directors is responsible for managing insider information and must maintain accurate and complete records of insider information personnel [1][2] - Insider information personnel must not disclose or trade based on insider information before it is publicly disclosed [2][3] - The company must keep insider information personnel records for at least 10 years and submit them to the Shanghai Stock Exchange within five trading days after public disclosure [4][5] Group 2: Definition and Scope of Insider Information - Insider information refers to undisclosed information that could significantly impact the company's operations, finances, or stock market price [3][4] - Insider information personnel include company directors, senior management, major shareholders, and others who can access insider information due to their roles or relationships with the company [2][3] Group 3: Registration and Record-Keeping - The company must fill out and maintain an insider information personnel record, documenting the stages of discussions, consultations, and decisions related to insider information [5][6] - The record must include details such as the name, identification number, relationship to the company, and the time and manner in which the insider information was obtained [5][6] Group 4: Confidentiality and Accountability - The company must implement strict confidentiality measures for insider information and hold personnel accountable for any breaches [9][10] - Violations of the insider information management system may lead to disciplinary actions, including potential criminal charges for severe breaches [10][11]

Core Points - The internal audit system aims to enhance corporate governance, standardize economic behavior, protect shareholder rights, and improve audit quality [1] - The internal audit department operates independently under the direct leadership of the board of directors and the audit committee, ensuring no interference from other departments [2][6] - Internal auditors must possess strong professional skills and adhere to ethical standards, maintaining independence and objectivity in their work [3][10] Group 1: Internal Audit Structure - The company has established an internal audit department responsible for supervising financial and operational activities of the company and its subsidiaries [2] - The internal audit department must remain independent and not be under the financial department's leadership [2] - The audit committee can commission the internal audit department for financial inspections when deemed necessary [7] Group 2: Responsibilities of Internal Audit - The internal audit department evaluates the effectiveness of internal controls and compliance with laws and regulations [4][6] - It is responsible for reporting significant issues directly to the audit committee and providing quarterly updates on audit plans and findings [4][5] - The department must focus on areas such as fraud prevention, financial reporting, and compliance with internal control systems [5][6] Group 3: Audit Procedures - The internal audit department develops an annual audit plan based on company priorities and past performance [11] - Audits are conducted following a structured process, including notifying the audited unit and documenting findings accurately [11][12] - Audit reports must be clear, supported by evidence, and accessible to non-professionals [12][36]

Core Points - The document outlines the information disclosure deferral and exemption management system for Dize (Jiangsu) Pharmaceutical Co., Ltd, aiming to standardize practices and protect the rights of shareholders and creditors [1][2][3] - The company is required to disclose significant events promptly, particularly when a board resolution is made or when relevant parties sign agreements [2][3] - The company can defer disclosure if it poses risks to its interests or could mislead investors, provided that confidentiality agreements are in place [2][3][4] Section Summaries General Provisions - The system is established based on relevant laws and regulations to ensure the company's lawful operation and protect stakeholders' rights [1] - The company can independently determine the need for deferral or exemption without prior application to the Shanghai Stock Exchange, subject to post-event supervision [1][2] Scope of Deferral and Exemption - Significant events must be disclosed at the earliest occurrence of specific milestones, such as board resolutions or when management becomes aware of the event [2] - If confidentiality is compromised or market rumors arise, the company must disclose relevant information within two trading days [2][3] Review Procedures for Deferral and Exemption - The company must carefully assess the need for deferral or exemption and prevent unauthorized disclosure of sensitive information [4][5] - A formal internal registration and approval process is required for any deferral or exemption, ensuring compliance with established criteria [5][6] Accountability and Compliance - The company must maintain a record of deferral and exemption actions and submit relevant materials to regulatory bodies within ten days after reporting periods [6][7] - A mechanism for accountability is established to address non-compliance with disclosure obligations, ensuring that responsible parties face appropriate consequences [6][7]

Core Points - The article outlines the rules and regulations governing the board of directors of Dize (Jiangsu) Pharmaceutical Co., Ltd, ensuring efficient decision-making and compliance with relevant laws [2][30]. Group 1: General Provisions - The board of directors is a permanent institution responsible for executing shareholder resolutions and safeguarding the interests of the company and all shareholders [2][3]. - The rules are established based on the Company Law, Securities Law, and the company's articles of association [2]. Group 2: Board Meetings - The board meetings are categorized into regular and temporary meetings, with at least two regular meetings required annually [6][7]. - Notifications for regular meetings must be sent at least 10 days in advance, while temporary meetings require a 5-day notice unless urgent [3][5]. - A temporary meeting must be convened under specific circumstances, such as a request from shareholders holding more than 10% of voting rights [4][6]. Group 3: Proposals and Voting - Proposals for board meetings must comply with legal and regulatory requirements and be within the board's authority [16][17]. - The chairman is responsible for drafting proposals after consulting with directors and management [17][18]. - Voting is conducted by a show of hands or written ballots, with each director having one vote [22][23]. Group 4: Meeting Records and Resolutions - Meeting records must include details such as the date, attendees, agenda, and voting results [27][28]. - Resolutions require a majority vote from attending directors, with specific conditions for certain decisions [24][25]. - The board secretary is responsible for maintaining meeting archives for at least 10 years [28].

Group 1 - The company, Dizhe Pharmaceutical, will hold its 2024 Annual General Meeting (AGM) on June 23, 2025, at 14:30 in Wuxi City [1][4] - Voting will be conducted through a combination of on-site and online methods, with specific time slots for each voting method [1][5] - The agenda includes a proposal to change the registered capital and amend the company’s articles of association, which has been approved by the board and supervisory committee [3][4] Group 2 - Shareholders must register to attend the AGM, with registration available from June 18, 2025, and specific documentation required for both individual and corporate shareholders [5][6] - The company will utilize the Shanghai Stock Exchange's online voting system, with voting available from 9:15 to 15:00 on the day of the meeting [1][4] - There are no related shareholders that need to abstain from voting on the proposed resolutions [3]

迪哲（江苏）医药股份有限公司 章 程 2025年5月 | | | 第一章 总 则 第一条 为维护迪哲（江苏）医药股份有限公司（以下简称"公司"）、股 东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）等法律法规和其他有关规定，制定本章程。 第二条 公司系依照《公司法》《证券法》及其他有关规定，由迪哲（江苏） 医药有限公司整体变更成立的股份有限公司。 公司依法在无锡市市场监督管理局登记，取得营业执照，统一社会信用代码 为：91320214MA1T6H5736。 第三条 公司于 2021 年 11 月 3 日经中华人民共和国证券监督管理委员会 （以下简称"中国证监会"）作出同意注册的决定，首次向社会公众发行人民币 普通股 4,000.01 万股，于 2021 年 12 月 10 日在上海证券交易所科创板上市。 第四条 公司注册名称 中文名称：迪哲（江苏）医药股份有限公司 英文名称：Dizal (Jiangsu) Pharmaceutical Co., Ltd. 第五条 公司住所：无锡市新吴区和风路 26 ...

股东会议事规则 第一章 总则 第一条 为规范迪哲（江苏）医药股份有限公司（以下简称"公司"）行为， 保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》《上 市公司治理准则》和《迪哲（江苏）医药股份有限公司章程》（以下简称"《公司 章程》"）以及国家的相关法律、法规及规范性文件的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时，临时股东会应当在 2 个月内召开。 迪哲（江苏）医药股份有限公司 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证券监督管 ...